Trials / Completed
CompletedNCT02913716
A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects
A Phase I, Open-label Study of the Absorption, Metabolism and Excretion of Defactinib (VS-6063-106) in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Verastem, Inc. · Industry
- Sex
- Male
- Age
- 40 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study assesses the mass balance recovery, pharmacokinetics, metabolite profile and metabolite identification of defactinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | defactinib | Single oral dose of 400 mg \[14C\]-defactinib |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2016-09-26
- Last updated
- 2017-01-30
Source: ClinicalTrials.gov record NCT02913716. Inclusion in this directory is not an endorsement.